

Supplemental Table 7. Associations between aging constructs and mortality in cancer survivors stratified by time since cancer diagnosis, HRS (2016-2020)

Sample A: 941 cancer survivors (5 survivors were excluded due to missing time of cancer diagnosis)			
	HR (95% CI)^b per 1 SD increase in age acceleration		
Time since cancer diagnosis	KDM-BA-Accel	PhenoAgeAccel	SA-Accel
<2 years (14 deaths out of 95 survivors)	1.35 (0.80, 2.31)	1.63 (0.79, 3.37)	1.07 (0.56, 2.09)
2-5 years (25 deaths out of 162 survivors)	1.02 (0.70, 1.46)	1.90 (1.07, 3.38)	0.91 (0.49, 1.71)
>5 years (83 deaths out of 683 survivors)	1.09 (0.88, 1.35)	1.34 (0.96, 1.86)	0.89 (0.62, 1.27)
Sample B: 577 cancer survivors (5 survivors were excluded due to missing time of cancer diagnosis)			
	HR (95% CI)^b per 1 SD increase in age acceleration		
Time since cancer diagnosis	HannumAccel	HorvathAccel	LevineAccel
<2 years (15 deaths out of 64 survivors)	1.33 (0.94, 1.86)	1.17 (0.88, 1.54)	3.84 (1.28, 11.54)
2-5 years (15 deaths out of 110 survivors)	1.32 (0.81, 2.61)	1.52 (0.98, 2.36)	2.41 (0.97, 6.01)
>5 years (73 deaths out of 403 survivors)	1.48 (1.14, 1.93)	1.23 (0.93, 1.61)	1.49 (1.21, 1.82)
Time since cancer diagnosis	GrimAgeAccel	POA	
<2 years (15 deaths out of 64 survivors)	2.77 (1.98, 3.89)	1.93 (1.49, 2.51)	
2-5 years (15 deaths out of 110 survivors)	3.08 (1.34, 7.07)	1.72 (0.35, 8.37)	
>5 years (73 deaths out of 403 survivors)	2.04 (1.30, 3.18)	1.10 (0.77, 1.58)	

^aSample A includes cancer survivors who had measures of KDM-BA, PhenoAge, and SA. Sample B includes cancer survivors who had data on ECs.

^bThe model was adjusted for chronological age, sex, race/ethnicity, BMI, smoking status, comorbidity index, and CMV infection.